Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics Inc. executive vice president and general counsel Alicia C. Olivo reported new equity awards. On March 1, 2026, she received 147,804 stock options and 89,013 restricted stock units as compensation, both granted at an exercise/issue price of $0.00 per share.
The stock options are described as premium-price options, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest in equal installments over the first three anniversaries of the grant date, and once vested, the related common shares are not subject to expiration.
Positive
- None.
Negative
- None.
Insider Trade Summary
18 transactions reported
Mixed
18 txns
Insider
Olivo Alicia C
Role
EVP, GC & Business Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 147,804 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 89,013 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 147,804 shares (Direct);
Restricted Stock Unit — 89,013 shares (Direct);
Performance Stock Unit — 19,508 shares (Direct);
Common Stock — 93,224 shares (Direct)
Footnotes (1)
- This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
FAQ
What insider transaction did NeoGenomics (NEO) report for Alicia C. Olivo?
NeoGenomics reported that EVP and general counsel Alicia C. Olivo received new equity awards. On March 1, 2026, she was granted stock options and restricted stock units as part of her compensation, rather than buying shares in the open market.
How many stock options were granted to NeoGenomics (NEO) executive Alicia C. Olivo?
Alicia C. Olivo was granted 147,804 stock options on March 1, 2026. These options vest in three equal annual installments and were issued as premium-price options with the exercise price set at 110% of a prior closing share price.
How many restricted stock units did Alicia C. Olivo receive from NeoGenomics (NEO)?
On March 1, 2026, Alicia C. Olivo received 89,013 restricted stock units. These RSUs vest ratably over the first three anniversaries of the grant date, providing time-based equity compensation tied to her continued service with NeoGenomics.
Over what period do Alicia C. Olivo’s new NeoGenomics (NEO) equity awards vest?
Both the 147,804 stock options and 89,013 restricted stock units granted to Alicia C. Olivo vest ratably over three years. The vesting occurs on the first, second, and third anniversaries of the March 1, 2026 grant date, contingent on continued service.
Do the NeoGenomics (NEO) equity awards to Alicia C. Olivo have an expiration once vested?
The Form 4 notes that once the related awards vest, the resulting shares of NeoGenomics common stock are not subject to expiration. This means vested shares remain outstanding without a time limit, subject to any separate trading or holding considerations.
Neogenomics Inc